ADC Therapeutics(ADCT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, net product revenues were $22.3 million, up from $16.4 million in Q4 2024, indicating a significant increase [23] - For the full year 2025, net product revenues reached $73.6 million, compared to $69.3 million in 2024, showing stable performance [23] - Total operating expenses for Q4 2025 were $41 million, while for the full year, they were $202.9 million, reflecting a disciplined cost management approach [23] - The net loss for Q4 2025 was $6.4 million, a significant improvement from a net loss of $30.7 million in Q4 2024 [25] - The full year net loss was $142.6 million, down from $157.8 million in 2024, primarily due to reduced R&D expenses [25] Business Line Data and Key Metrics Changes - The company focused on ZYNLONTA, achieving a stable revenue stream in the third-line plus DLBCL setting, with a strong Q4 performance driven by new account activations [5][9] - The strategic reprioritization led to a reduction in operating costs by approximately 50%, enhancing the company's financial flexibility [5][8] Market Data and Key Metrics Changes - The company anticipates a peak annual revenue opportunity of $600 million to $1 billion for ZYNLONTA, contingent on regulatory approval and compendia inclusion [7][12] - The treatment landscape for DLBCL is evolving, with a current 60/40 split between complex therapies and broadly accessible therapies, indicating a competitive market environment [16] Company Strategy and Development Direction - The strategic plan focuses on optimizing lifecycle management for ZYNLONTA, including advancing LOTIS-5 and initiating LOTIS-7 [5][6] - The company aims to establish ZYNLONTA as a backbone therapy in second-line plus DLBCL, while also expanding into indolent lymphomas [6][12] - The management emphasized the importance of maintaining a strong cash position to support ongoing and future clinical trials [11][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving significant long-term growth starting in 2027, driven by anticipated data catalysts and regulatory approvals [28] - The company remains optimistic about the potential for ZYNLONTA to reach a broader patient population through expanded indications [12][19] Other Important Information - The company ended 2025 with a cash balance of $261 million, providing a cash runway into 2028 [26] - An amendment to the royalty purchase agreement with HealthCare Royalty was made, enhancing strategic flexibility [11] Q&A Session Summary Question: How are PFS events tracking for LOTIS-5? - Management is confident in the Q2 timing for the top-line readout and will share primary and secondary endpoints at that time [30][31] Question: Is the $200-$300 million opportunity for LOTIS-5 conservative? - Management believes the profile seen in the safety run-in supports a meaningful role in second-line plus DLBCL, with potential for higher sales if the clinical profile is favorable [35][36] Question: What is the expected R&D spend going forward? - R&D expenses are expected to decrease in 2026 and 2027, assuming the current number of trials remains stable [43][45] Question: How should capital allocation priorities be viewed? - The company is focused on driving ZYNLONTA growth and has allocated capital for ongoing trials and pre-launch activities [48][51] Question: What is the current commercial run rate for ZYNLONTA? - Management is pleased with maintaining market share despite increased competition and anticipates significant sales growth with LOTIS-5 approval [60][61]